Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Eur J Nutr ; 57(8): 2897-2911, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29127476

RESUMEN

PURPOSE: Cranberries are a rich source of polyphenolic antioxidants. Purified sugars or artificial sweeteners are being added to cranberry-based food products to mask tartness. Refined sugar and artificial sweeteners intake modulate gut microbiota and result in metabolic complications. We evaluated effects of isomalto-oligosaccharides (IMOs; sweet tasting non-digestible oligosaccharides) with cranberry extract (CRX) on high fat diet (HFD)-induced metabolic alterations in mice. METHODS: Male Swiss albino mice were fed normal chow or HFD (58% fat kcal), and were administered either CRX (200 mg/kg) alone or in combination with IMOs (1 g/kg). Cecal short-chain fatty acids, abundances of selected (1) butyrate producing, (2) metabolically beneficial, and (3) selective lipopolysaccharides producing gram negative gut bacteria were studied. Further, gut-related histological, biochemical, genomic changes along with circulating pro-/anti-inflammatory markers and systemic obesity-associated metabolic changes were studied. RESULTS: Co-supplementation of CRX and IMOs significantly improved cecal SCFAs, especially butyrate levels, selected butyrate-producing bacteria (clostridial cluster XIVa bacteria) and butyrate kinase expression in HFD-fed mice. The combination also significantly improved gut beneficial bacterial abundance, gut histology and related changes (colon mucin production, gut permeability) as compared to individual agents. It also prevented HFD-induced systemic and tissue inflammation, glucose intolerance and systemic obesity-associated metabolic changes in adipose tissue and liver. The combination of CRX and IMOs appeared more effective in the prevention of HFD-induced gut derangements. CONCLUSION: Combination of CRX and IMOs could be advantageous for normalization of metabolic alterations seen in diet-induced obesity via beneficial modulation of gastrointestinal health.


Asunto(s)
Butiratos/metabolismo , Síndrome Metabólico/tratamiento farmacológico , Oligosacáridos/farmacología , Extractos Vegetales/farmacología , Vaccinium macrocarpon/química , Animales , Ciego/efectos de los fármacos , Ciego/metabolismo , Colon/efectos de los fármacos , Colon/metabolismo , Citocinas/sangre , Dieta Alta en Grasa/efectos adversos , Suplementos Dietéticos , Ácidos Grasos/metabolismo , Frutas/química , Microbioma Gastrointestinal/efectos de los fármacos , Intolerancia a la Glucosa/metabolismo , Inflamación/tratamiento farmacológico , Lipopolisacáridos/metabolismo , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/etiología , Ratones , Obesidad/tratamiento farmacológico , Polifenoles/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA